Zacks.com on MSN11h
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival GoalAstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...
Several launches in 2027 (Amgen, Altimmune), 2028 (Pfizer, Roche, Viking, and Structure), and 2029 (Roche, Viking, ...
The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...
More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
UMC Utrecht (LJB and NIM) received grants from AbbVie, AstraZeneca, The Bill & Melinda Gates Foundation, the Dutch Lung Foundation, The Gates Medical Research Institute, GlaxoSmithKline (GSK), Janssen ...
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback